Acute Kidney Injury with Severe Hypokalemia

Published:September 01, 2022DOI:
      A patient with acute kidney injury and severe hypokalemia was successfully treated with lanreotide and a single activity of peptide receptor radionuclide therapy (PRRT).
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Metz DC
        • Jensen RT.
        Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors.
        Gastroenterology. 2008; 135: 1469-1492
        • Perry RR
        • Vinik AI.
        Clinical review 72: diagnosis and management of functioning islet cell tumors.
        J Clin Endocrinol Metab. 1995; 80: 2273-2278
        • Bloom SR
        • Polak JM
        • Pearse AG.
        Vasoactive intestinal peptide and watery-diarrhoea syndrome.
        Lancet. 1973; 2: 14-16
        • Kos-Kudla B
        • Rosiek V
        • Borowska M
        • et al.
        Pancreatic neuroendocrine neoplasms - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours).
        Endokrynol Pol. 2017; 68: 169-197
        • Pavel M
        • O'Toole D
        • Costa F
        • et al.
        ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site.
        Neuroendocrinology. 2016; 103: 172-185
        • Starr JS
        • Sonbol MB
        • Hobday TJ
        • Sharma A
        • Kendi AT
        • Halfdanarson TR.
        Peptide receptor radionuclide therapy for the treatment of pancreatic neuroendocrine tumors: recent insights.
        Onco Targets Ther. 2020; 13: 3545-3555